BRPI9911389B8 - peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo - Google Patents

peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo

Info

Publication number
BRPI9911389B8
BRPI9911389B8 BRPI9911389A BR9911389A BRPI9911389B8 BR PI9911389 B8 BRPI9911389 B8 BR PI9911389B8 BR PI9911389 A BRPI9911389 A BR PI9911389A BR 9911389 A BR9911389 A BR 9911389A BR PI9911389 B8 BRPI9911389 B8 BR PI9911389B8
Authority
BR
Brazil
Prior art keywords
peptide
ige
well
conjugate
pharmaceutical composition
Prior art date
Application number
BRPI9911389A
Other languages
English (en)
Other versions
BRPI9911389B1 (pt
BR9911389A (pt
Inventor
M Walfield Alan
Yi Wang Chang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of BR9911389A publication Critical patent/BR9911389A/pt
Publication of BRPI9911389B1 publication Critical patent/BRPI9911389B1/pt
Publication of BRPI9911389B8 publication Critical patent/BRPI9911389B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

patente de invenção: <b>"composição de peptídio como imunógeno para o tratamento de alergia"<d>. a presente invenção apresenta peptídios que compeendem uma seqüência homóloga a uma porção do terceiro domínio constante da cadeia pesada epsílon da ige, covalentemente ligada ou a (1) uma proteína carreadora, ou a (2) um epítopo de célula auxiliar t e, opcionalmente, também a outras seqüências imunoestimuladoras. a presente invenção apresenta o uso de tais peptídios como imunógenos para acarretar a produção em mamíferos de anticorpos policlonais de elevada titulação, os quais são específicos para um sítio de efetor alvo na cadeia pesada epsílon de ige. os peptídios devem ser úteis em composições farmacêuticas, para que se obtenha uma imunoterapia para doenças alérgicas mediadas por ige.
BRPI9911389A 1998-06-20 1999-06-21 peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo BRPI9911389B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10028798A 1998-06-20 1998-06-20
US09/100,287 1998-06-20
PCT/US1999/013959 WO1999067293A1 (en) 1998-06-20 1999-06-21 Peptide composition as immunogen for the treatment of allergy

Publications (3)

Publication Number Publication Date
BR9911389A BR9911389A (pt) 2001-03-20
BRPI9911389B1 BRPI9911389B1 (pt) 2018-03-20
BRPI9911389B8 true BRPI9911389B8 (pt) 2021-05-25

Family

ID=22279023

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9911389A BRPI9911389B8 (pt) 1998-06-20 1999-06-21 peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo

Country Status (14)

Country Link
US (2) US6811782B1 (pt)
EP (1) EP1090039B1 (pt)
JP (1) JP4031201B2 (pt)
CN (1) CN1259340C (pt)
AT (1) ATE429448T1 (pt)
AU (1) AU757919B2 (pt)
BR (1) BRPI9911389B8 (pt)
CA (1) CA2329754C (pt)
DE (1) DE69940775D1 (pt)
DK (1) DK1090039T3 (pt)
HK (1) HK1036804A1 (pt)
TW (1) TWI227241B (pt)
WO (1) WO1999067293A1 (pt)
ZA (1) ZA200006384B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
BR9915771A (pt) 1998-11-30 2001-12-26 Cytos Biotechnology Ag Apresentação molecular ordenada de antìgenos,processo de preparação e utilização
PL350992A1 (en) * 1999-02-25 2003-02-24 Smithkline Beecham Biolog Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
CN1418222A (zh) * 2000-01-14 2003-05-14 第一制药株式会社 新的肽以及使用该肽的筛选方法
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
GB0020717D0 (en) * 2000-08-22 2000-10-11 Smithkline Beecham Biolog Novel compounds and process
EP2065052A3 (en) * 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
DE60233231D1 (de) * 2001-05-15 2009-09-17 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
MXPA04012443A (es) * 2002-06-11 2005-04-19 Glaxosmithkline Biolog Sa Composiciones inmunogenicas.
AU2003243663A1 (en) 2002-06-20 2004-01-06 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
CA2489410C (en) 2002-07-17 2015-01-13 Cytos Biotechnology Ag Molecular antigen arrays
IN2008CN05409A (pt) 2002-07-18 2015-10-02 Cytos Biotechnology Ag
WO2004016282A1 (en) 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
EP1709073B1 (en) * 2003-11-26 2011-08-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)
SG183683A1 (en) * 2004-02-02 2012-09-27 Tanox Inc Identification of novel ige epitopes
US8080249B2 (en) * 2005-06-30 2011-12-20 Risk Glifford G Methods to treating chronic obstructive pulmonary disease
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US8507646B2 (en) * 2007-02-23 2013-08-13 Landing Biotech, Inc. Treating atherosclerosis
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
AU2013204233B2 (en) * 2008-12-09 2015-06-25 Pfizer Vaccines Llc IgE CH3 peptide vaccine
KR101644221B1 (ko) * 2008-12-09 2016-07-29 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
MX2012002639A (es) * 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
EP2942061A3 (en) * 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
CN104395337A (zh) * 2012-06-18 2015-03-04 日本全药工业株式会社 IgE肽疫苗
CN104558196A (zh) * 2013-10-15 2015-04-29 温州医科大学 基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途
US20170216418A1 (en) * 2014-07-25 2017-08-03 United Biomedical, Inc. Immunogenic lhrh composition and use thereof in pigs
JP2019528071A (ja) * 2016-08-23 2019-10-10 エイムヴィオン・アクティエセルスカブＡｉｍＶｉｏｎ Ａ／Ｓ 新規免疫刺激ペプチド
EP3731934A1 (en) * 2017-12-31 2020-11-04 United Biomedical, Inc. Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases
EP4213874A1 (en) 2020-09-17 2023-07-26 Neovacs Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940782A (en) 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
EP0602126B1 (en) * 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
CA2161445C (en) 1993-04-27 2009-06-30 Anna Efim Ladd Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
EP0811016A1 (en) * 1994-03-28 1997-12-10 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
JPH09169795A (ja) 1995-12-22 1997-06-30 Hitachi Chem Co Ltd イヌ免疫グロブリンｅペプチド断片、それをコードするｄｎａ、そのｄｎａを含む組換えベクター、その組換えベクターを含む形質転換体及び抗イヌ免疫グロブリンｅ抗体の製造法
AU6532498A (en) * 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
BRPI9911389B1 (pt) 2018-03-20
ATE429448T1 (de) 2009-05-15
AU4580299A (en) 2000-01-10
EP1090039A1 (en) 2001-04-11
ZA200006384B (en) 2001-05-29
CA2329754C (en) 2011-12-20
US7648701B2 (en) 2010-01-19
WO1999067293A1 (en) 1999-12-29
CN1305498A (zh) 2001-07-25
TWI227241B (en) 2005-02-01
BR9911389A (pt) 2001-03-20
JP2002518038A (ja) 2002-06-25
HK1036804A1 (en) 2002-01-18
US20050250934A1 (en) 2005-11-10
CN1259340C (zh) 2006-06-14
EP1090039A4 (en) 2002-08-07
CA2329754A1 (en) 1999-12-29
EP1090039B1 (en) 2009-04-22
JP4031201B2 (ja) 2008-01-09
AU757919B2 (en) 2003-03-13
DK1090039T3 (da) 2009-07-27
DE69940775D1 (de) 2009-06-04
US6811782B1 (en) 2004-11-02

Similar Documents

Publication Publication Date Title
BRPI9911389B8 (pt) peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo
Ellouz et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives
ATE447585T1 (de) Antigener komplex, der ein immunstimulierendes peptid enthält, cd4 und chemokinrezeptor-domäne zur behandlung von hiv und immunerkrankungen
JP2921574B2 (ja) 接合体ワクチンの担体分子としてのｔ細胞のエピトープ
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
HUP0004639A2 (hu) Chlamydia fehérje, génszekvencia és ezek alkalmazása
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
BRPI9912177B8 (pt) epítopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptídeo sintéticos, imunógenos de peptídeo e método para a produção dos mesmos
NZ612796A (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same
WO2001093913A3 (en) T cell receptor fusions and conjugates and methods of use thereof
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
ES2181752T3 (es) Conjugados de agentes antitumorales de metiltritio y productos intermedios para su sintesis.
Hervé et al. On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules
KR890004730A (ko) G_7rh에 대한 면역반응을 유발시키고 포유동물을 면역 불임시키기 위한 제제 및 방법
WO1993012145A1 (en) Pva or peg conjugates of peptides for epitope-specific immunosuppression
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
Hudecz Manipulation of epitope function by modification of peptide structure: a minireview
ATE94880T1 (de) Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung.
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
NO950526L (no) T-celleepitoper av raigresspollen-allergen
PT996636E (pt) Antigenio ha-1
Morrison et al. Computer‐aided design and physiological testing of a luteinising hormone‐releasing hormone analogue for ‘adjuvant‐free’immunocastration
BR9911388A (pt) Imunógeno de somatostatina sintético para promoção de crescimento em animais de fazenda

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/03/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/06/2019